Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Ad-hoc News: Mercedes-Benz Group AG (EQS) +++ MERCEDES-BENZ Aktie -3,02%

SWEDISH ORPHAN Aktie

 >SWEDISH ORPHAN Aktienkurs 
42.3 EUR    +3.0%    (TradegateBSX)
Ask: 42.16 EUR / 120 Stück
Bid: 42.1 EUR / 120 Stück
Tagesumsatz: 645 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>SWEDISH ORPHAN Performance
1 Woche: +1,5%
1 Monat: +6,0%
3 Monate: -0,3%
6 Monate: +12,2%
1 Jahr: +40,1%
laufendes Jahr: +33,7%
>SWEDISH ORPHAN Aktie
Name:  SWEDISH ORPHAN BIOVITRUM
Land:  Schweden
Sektor:  Gesundheit
ISIN/ Wkn:  SE0000872095 / A0LA5K
Symbol/ Ticker:  B6E (Frankfurt)
Kürzel:  FRA:B6E, ETR:B6E, B6E:GR
Index:  -
Webseite:  https://www.sobi.com/
Profil:  Swedish Orphan Biovitrum AB is an international biopharmaceutical company headquartered in Stockholm, Sweden, specializing in treatments for rare diseases within haematology, immunology, and specialty care. It focuses on researching, developing, manu..
>Volltext..
Marktkapitalisierung:  14061.87 Mio. EUR
Unternehmenswert:  15548.65 Mio. EUR
Umsatz:  2807.44 Mio. EUR
EBITDA:  1790.46 Mio. EUR
Nettogewinn:  126.7 Mio. EUR
Gewinn je Aktie:  0.36 EUR
Schulden:  1612.33 Mio. EUR
Liquide Mittel:  99.2 Mio. EUR
Operativer Cashflow:  720.68 Mio. EUR
Bargeldquote:  0.05
Umsatzwachstum:  14.33%
Gewinnwachstum:  -68.17%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  SWEDISH ORPHAN
Letzte Datenerhebung:  27.10.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 347.51 Mio. St.
Frei handelbar: 52.16%
Leerverk. Aktien: -
Rückkaufquote: -0.22%
Mitarbeiter: 1888
Umsatz/Mitarb.: 1.44 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 19.66%
Bewertung:
KGV: 112.42
KGV lG: 22.8
KUV: 4.84
KBV: 3.56
PEG-Ratio: -
EV/EBITDA: 8.68
Rentabilität:
Bruttomarge: 45.32%
Gewinnmarge: 4.51%
Operative Marge: 30.12%
Managementeffizenz:
Gesamtkaprendite: 1.82%
Eigenkaprendite: 3.4%
>Peer Group
Gesundheit, Lebererkrankungen & -behandlung/ Hepatitis, Lungen- & Atemwegserkrankungen/ -behandlung
 
27.10.26 - 09:42
 Swedish Orphan Biovitrum Swings To Profit In Q3; Updates FY26 View; Stock Up 2.9% (AFX)
 
STOCKHOLM (dpa-AFX) - Swedish Orphan Biovitrum AB (SWOBY, BIOVF, SOBI.ST) Tuesday said that it turned to a profit in the third quarter of 2026 from last year's loss, helped by higher revenues, esp......
27.10.26 - 09:33
 Sobi Q3 2026 report: Underpinning a strong growth momentum (PR Newswire)
 
STOCKHOLM, Oct. 27, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2026 Third Quarter 2026 Total revenue increased 16 per cent at CER (constant exchange rates), 17 per cent at actual rates, to SEK 9,124 M (7,776), leading......
27.10.26 - 09:30
 Swedish Orphan Biovitrum: Starke Quartalszahlen und angehobene Prognose beflügeln Aktie (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
27.10.26 - 09:27
 Sobi Q3 2026 report: Underpinning a strong growth momentum (PR Newswire)
 
STOCKHOLM, Oct. 27, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2026 Third Quarter 2026 Total revenue increased 16 per cent at CER (constant exchange rates), 17 per cent at actual rates, to SEK 9,124 M (7,776), leading......
12.10.26 - 17:30
 Earnings Preview: Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Expected to Decline (Zacks)
 
Swedish Orphan Biovitrum (BIOVF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
30.09.26 - 08:21
 Change in number of shares and votes in Sobi (PR Newswire)
 
STOCKHOLM, Sept. 30, 2026 /PRNewswire/ -- As per 30 September 2026, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,636,514 shares. All shares are common shares. The total number of votes is 357,636,514. The increase in the number of shares and......
30.09.26 - 08:15
 Change in number of shares and votes in Sobi (PR Newswire)
 
STOCKHOLM, Sept. 30, 2026 /PRNewswire/ -- As per 30 September 2026, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,636,514 shares. All shares are common shares. The total number of votes is 357,636,514. The increase in the number of shares and......
17.09.26 - 05:33
 Sobi and Innate announce partnership is now effective following completion of closing conditions (PR Newswire)
 
STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that the previously announced strategic partnership with Innate is now effective following the......
31.08.26 - 12:36
 Sobi has completed an issue of class C shares (PR Newswire)
 
STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 6 May 2026 resolved on a directed issue of redeemable and convertible class C shares and to authorise the Board of Directors to resolve on the repurchase of all issued......
31.08.26 - 12:30
 Sobi has completed an issue of class C shares (PR Newswire)
 
STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 6 May 2026 resolved on a directed issue of redeemable and convertible class C shares and to authorise the Board of Directors to resolve on the repurchase of all issued......
10.08.26 - 09:36
 Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma (AFX)
 
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Swedish Orphan Biovitrum AB (SOBI.ST) and Innate Pharma (IPHA, IPH, IPH.PA) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirm......
10.08.26 - 08:39
 Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma (PR Newswire)
 
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory......
10.08.26 - 08:33
 Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma (PR Newswire)
 
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory......
03.08.26 - 11:24
 BioNTech: Jetzt ist die Katze aus dem Sack (Der Aktionaer)
 
Der mRNA-Spezialist BioNTech hat einen Nachfolger für den scheidenden CEO und Co-Gründer Ugur Sahin gefunden. Guido Oelkers, derzeit noch Firmenlenker beim skandinavischen Biopharma-Unternehmen Swedish Orphan Biovitrum (SOBI), wird spätestens zum 01....
03.08.26 - 11:06
 CEO-Rücktritt belastet Aktie von Swedish Orphan Biovitrum (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
03.08.26 - 11:03
 BioNTech ernennt Dr. Guido Oelkers zum neuen Vorstandsvorsitzenden (GlobeNewswire)
 
Mainz, Deutschland, 3. August 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Dr. Guido Oelkers zum neuen Vorstandsvorsitzenden (Chief Executive Officer, „CEO“) der BioNTech SE ernannt hat, der sein Amt spätestens zum 1. Februar 2027 antreten wird. Er wird damit auf Prof. Dr. Ugur Sahin folgen. Guido Oelkers wechselt von dem global tätigen, an der Nasdaq Stockholm notierten Biopharmaunternehmen Swedish Orphan Biovitrum AB (STO: SOBI, „Sobi“), bei dem er seit 2017 als Vorstandsvorsitzender tätig war, zu BioNTech....
03.08.26 - 11:03
 BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer (GlobeNewswire EN)
 
Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer (“CEO”), who will take office by February 1, 2027, at the latest. Succeeding Prof. Ugur Sahin, M.D., Guido Oelkers will join BioNTech from the global Nasdaq Stockholm-listed biopharmaceutical company Swedish Orphan Biovitrum AB (STO: SOBI, “Sobi”), where he has served as CEO since 2017....
03.08.26 - 10:48
 CEO-Wechsel bei Swedish Orphan Biovitrum belastet die Aktie (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
03.08.26 - 08:12
 SOBI CEO Guido Oelkers To Step Down 2027 Beginning (AFX)
 
STOCKHOLM (dpa-AFX) - Swedish Orphan Biovitrum AB (SOBI.ST), a biopharma company, Monday announced that its Chief Executive Officer, Guido Oelkers has decided to step down from his role to take up......
03.08.26 - 07:33
 Guido Oelkers to step down as CEO of Sobi in the beginning of 2027 (PR Newswire)
 
STOCKHOLM, Aug. 3, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announces that Guido Oelkers has informed the Board of Directors that he has decided to step down as Chief Executive Officer of Sobi to take up another position outside Sobi. Guido Oelkers will remain......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Tandem bona causa triumphat - Endlich triumphiert die gute Sache. - Nomen Nescio
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!